drug_name,smiles,toxtype,canonical_smiles
BIA 10-2474,CN(C(=O)N1C=NC(C2=CC=C[N+]([O-])=C2)=C1)C1CCCCC1,Nervous system disorders,CN(C(=O)n1cnc(-c2ccc[n+]([O-])c2)c1)C1CCCCC1
Acomplia,CC1=C(C2=CC=C(Cl)C=C2)N(C2=CC=C(Cl)C=C2Cl)N=C1C(=O)NN1CCCCC1,Nervous system disorders,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
Rubraca,N(CC1=CC=C(/C2=C3/C4=C(C=C(F)C=C4N2)C(=O)NCC3)C=C1)C,,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
lanifibranor,O=C(O)CCC/C1=C/C2=CC(Cl)=CC=C2N1S(C1=C\C=C2\N=CS\C2=C\1)(=O)=O,Hepatobiliary disorders,O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1
hydroxychloroquine,CCN(CCO)CCCC(C)N/C1=C/C=N\C2=CC(Cl)=CC=C12,Cardiac disorders,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Nuplazid,CN1CCC(N(CC2=CC=C(F)C=C2)C(=O)NCC2=CC=C(OCC(C)C)C=C2)CC1,,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
Atabecestat,C[C@@]1(C2=CC(NC(=O)C3=CC=C(C#N)C=N3)=CC=C2F)C=CSC(N)=N1,Hepatobiliary disorders,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1
Finerenone,CCOC1=NC=C(C)C2=C1[C@H](C1=CC=C(C#N)C=C1OC)C(C(N)=O)=C(C)N2,Renal and urinary disorders;Cardiac disorders;Vascular disorders,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2
Iptacopan,CCO[C@H]1CCN(C/C2=C(OC)/C=C(/C)C3=C2C=CN3)[C@H](C2=CC=C(C(=O)O)C=C2)C1.Cl,,CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@H](c2ccc(C(=O)O)cc2)C1
Aficamten,CCC1=NC(C2=CC=C3C(=C2)CC[C@H]3NC(=O)C2=CN(C)N=C2)=NO1,,CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1
Resmetirom,N#CC1=NN(C2=CC(Cl)=C(OC3=NNC(=O)C(C(C)C)=C3)C(Cl)=C2)C(=O)NC1=O,,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O
BAY2413555,C[C@H](NC(=O)/C1=C/N(C2=C(F)C=C(F)C=C2F)C2=NC(N3C[C@@H](O)[C@H](O)C3)=C(F)C=C2C1=O)C(C(F)(F)F)(F)F,,C[C@H](NC(=O)c1cn(-c2c(F)cc(F)cc2F)c2nc(N3C[C@@H](O)[C@H](O)C3)c(F)cc2c1=O)C(F)(F)C(F)(F)F
NVP-DFV890,N[S@@](=O)(=NC(=O)NC1=C2C(=CC3=C1CCC3)CCC2)C1=CN=C(C(O)(C)C)S1,,CC(C)(O)c1ncc([S@](N)(=O)=NC(=O)Nc2c3c(cc4c2CCC4)CCC3)s1
AZD4144,OC[C@@H](O)CN/C1=N/N=C(/C2=CC=C(C(F)(F)F)C=C2O)C2=CC=CC=C12,,OC[C@@H](O)CNc1nnc(-c2ccc(C(F)(F)F)cc2O)c2ccccc12
JT001,O=C(NC1=C2C(=CC3=C1CCC3)CCC2)NS(C1=C2N(N=C1)CCCO2)(=O)=O,Renal and urinary disorders,O=C(Nc1c2c(cc3c1CCC3)CCC2)NS(=O)(=O)c1cnn2c1OCCC2
sovleplenib,CS(N1CCC(C2=CC=C(C3=C/C4=NC=CN=C4/C(NC[C@@H]4CNCCO4)=N\3)C=C2)CC1)(=O)=O,,CS(=O)(=O)N1CCC(c2ccc(-c3cc4nccnc4c(NC[C@@H]4CNCCO4)n3)cc2)CC1
STX-478,C/C1=C(\[C@@H](NC(=O)NC2=CN=C(N)N=C2)C(F)(F)F)OC2=C(F)C=C(F)C=C12,Off-target side effects hyperglycemia and rash,Cc1c([C@@H](NC(=O)Nc2cnc(N)nc2)C(F)(F)F)oc2c(F)cc(F)cc12
inavolisib,C[C@H](NC1=CC=C2C(=C1)OCCN1C=C(N3C(=O)OC[C@H]3C(F)F)N=C21)C(N)=O,hyperglycemia and rash,C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O
alpelisib,CC1=C(C2=CC=NC(C(C(F)(F)F)(C)C)=C2)SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1,hyperglycemia and rash,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
Duvelisib,C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,"common severe side effects include neutropenia (30%), diarrhea (15%), anemia (13%), and colitis (12%)",C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
Idelalisib,[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,has a higher rate of severe or potentially fatal liver toxicity,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1
Leniolisib,CCC(=O)N1CC[C@@H](C1)NC1=C2CN(CCC2=NC=N1)C1=CN=C(OC)C(=C1)C(F)(F)F,,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1
Copanlisib,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21,increase blood pressure,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21
Buparlisib,NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F,,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1
GDC-0941,CS(N1CCN(C/C2=C/C3=NC(/C4=C/C=C\C5=C4C=NN5)=NC(N4CCOCC4)=C3S2)CC1)(=O)=O,,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1
pilaralisib,COC1=CC=C(Cl)C(NC2=C(NS(=O)(=O)C3=CC(NC(=O)C(C)(C)N)=CC=C3)N=C3C=CC=CC3=N2)=C1,,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1
RLY-2608,N#C/C1=C(C2=CC(NC(=O)C3=CC(F)=CC(C(F)(F)F)=C3)=C3C(=C2)C(=O)N[C@H]3C2=CC(F)=CC=C2Cl)/C=C\C2=NC=NN12,without hyperglycemia,N#Cc1c(-c2cc(NC(=O)c3cc(F)cc(C(F)(F)F)c3)c3c(c2)C(=O)N[C@H]3c2cc(F)ccc2Cl)ccc2ncnn12
NVL-520,CCN1N=CC2=C1C1=CN=C(N)C(=C1)O[C@H](C)C1=CC(F)=CC=C1C1=NN(C)N=C1C2,Off-target side effects,CCn1ncc2c1-c1cnc(N)c(c1)O[C@H](C)c1cc(F)ccc1-c1nn(C)nc1C2
Fenebrutinib,C[C@H]1CN(C2COC2)CCN1C1=CC=C(NC2=CC(C3=CC=NC(N4CCN5C(=CC6=C5CC(C)(C)C6)C4=O)=C3CO)=CN(C)C2=O)N=C1,,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
AZD4747,C=CC(=O)N1CCN2CC3=CC(C#CC)=C(C4=C(O)C=CC=C4Cl)C(F)=C3OC[C@H]2C1,,C=CC(=O)N1CCN2Cc3cc(C#CC)c(-c4c(O)cccc4Cl)c(F)c3OC[C@H]2C1
LY3499446,C=CC(=O)N1CCN(CC1)c1ncnc2c1cc(Cl)c(c2F)c1ccc(c2c1nc(s2)N)F,clinical trial was discontinued due to toxicity,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4ccc(F)c5sc(N)nc45)c(Cl)cc23)CC1
JDQ443,C=CC(=O)N1CC2(CC(N3N=C(C4=CC=C5C(=C4)C=NN5C)C(/C4=C(Cl)/C(C)=C\C5=C4C=NN5)=C3C)C2)C1,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1
ERAS-5024,N#C/C1=C(\N)SC2=C(F)C=CC(C3=C(C(F)(F)F)\C=C4\C(N5CC6NC(C5)CC6)=NC(OC[C@@]56CCCN5C[C@H](F)C6)=N\C4=C\3F)=C12,"pseudo-allergic reactions,In vivo toxicologic",N#Cc1c(N)sc2c(F)ccc(-c3c(C(F)(F)F)cc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12
MRTX-1133,C#C/C1=C(F)/C=C\C2=CC(O)=CC(C3=N\C=C4\C(N5CC6NC(C5)CC6)=NC(OC[C@@]56CCCN5C[C@H](F)C6)=N\C4=C\3F)=C12,,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12
RMC-9805,CO[C@@H](C)C1=NC=C(N2CCN(C3CC3)CC2)C=C1/C1=C2/C3=CC(=CC=C3N1CC(F)(F)F)N1CCO[C@@H](C[C@H](NC(=O)[C@H](C3CCCC3)N3CC[C@]4(CCN(C(=O)[C@H]5[C@@H](C6CC6)N5C)C4)C3)C(=O)N3CCC[C@H](N3)C(=O)OCC(C)(C)C2)C1,,CO[C@@H](C)c1ncc(N2CCN(C3CC3)CC2)cc1-c1c2c3cc(ccc3n1CC(F)(F)F)N1CCO[C@@H](C[C@H](NC(=O)[C@H](C3CCCC3)N3CC[C@]4(CCN(C(=O)[C@H]5[C@@H](C6CC6)N5C)C4)C3)C(=O)N3CCC[C@H](N3)C(=O)OCC(C)(C)C2)C1
TNO155,C[C@@H]1OCC2([C@@H]1N)CCN(C1=CN=C(SC3=CC=NC(N)=C3Cl)C(N)=N1)CC2,"Ph.1 trial shows a good safety,but the drug activity is not good",C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Deucravacitinib,[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Brepocitinib,CN1C=C(NC2=NC=CC(N3CC4N(C(=O)[C@@H]5CC5(F)F)C(C3)CC4)=N2)C=N1,,Cn1cc(Nc2nccc(N3CC4CCC(C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
MK-8666,CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC(COC2=CC3=C(C=N2)[C@H]2[C@@H](C3)[C@@H]2C(O)=O)=CC=C1,Hepatobiliary disorders,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2cc3c(cn2)[C@H]2[C@@H](C3)[C@@H]2C(=O)O)c1
PF-06939999,CC1=NC=NC2=C1C=CN2[C@@H]1CC(OC2=CC(C(F)F)=C(F)C3=C2CNCC3)[C@@H](O)[C@H]1O,Blood and lymphatic system disorders,Cc1ncnc2c1ccn2[C@@H]1CC(Oc2cc(C(F)F)c(F)c3c2CNCC3)[C@@H](O)[C@H]1O
Tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,Cardiac disorders;Vascular disorders,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Peficitinib,NC(=O)C1=CN=C2NC=CC2=C1N[C@H]1[C@H]2CC3C[C@@H]1C[C@@](O)(C3)C2,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@](O)(C3)C2
Baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,Cardiac disorders;Vascular disorders,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
ruxolitinib,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
delgocitinib,C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)C1=C2C=CNC2=NC=N1,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
momelotinib,O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Upadacitinib,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,Cardiac disorders;Vascular disorders,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Filgotinib,O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1,Cardiac disorders;Vascular disorders,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Itacitinib,FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Abrocitinib,CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Fedratinib,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Pacritinib,C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1
Ritlecitinib,C[C@H]1CC[C@H](CN1C(=O)C=C)NC1=NC=NC2=C1C=CN2,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
Decernotinib,CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F,,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F
palbociclib,CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O,,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1,,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1
abemaciclib,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1,,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1
Tagtociclib,CC(C)NC(=O)O[C@@H]1CC[C@@H](C1)C2=CC(=NN2)NC(=O)C3=CC(=NN3C)COC,,COCc1cc(C(=O)Nc2cc([C@H]3CC[C@@H](OC(=O)NC(C)C)C3)[nH]n2)n(C)n1
Avotaciclib,NC1=NC=CC(=N1)C1=NC(=C(O)C=C1)C1=NC(N)=NC=C1,,Nc1nccc(-c2ccc(O)c(-c3ccnc(N)n3)n2)n1
roniciclib,C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C2CC2)=N1)C(F)(F)F,,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F
alvocidib,CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl,,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1
seliciclib,CC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1,,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1
Dinaciclib,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO,,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12
Berotralstat (BCX7353),NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F,Cardiac disorders,N#Cc1cccc([C@@H](NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1
MORF-627,FC1=CC=C([C@@H]2OCC3(CC3)CC2)C([C@@H](C(O)=O)N4C[C@H](OCCCCC5=CC=C(CCCN6)C6=N5)CC4)=C1,Carcinogenic toxicity,O=C(O)[C@H](c1cc(F)ccc1[C@H]1CCC2(CC2)CO1)N1CC[C@@H](OCCCCc2ccc3c(n2)NCCC3)C1
IAG933,CNC(=O)C1=CN=C(C(=C1C2=C3C[C@@](OC3=CC(=C2Cl)F)([C@@H]4CCCN4)C5=CC=CC=C5)F)OCCO,Cardiac disorders,CNC(=O)c1cnc(OCCO)c(F)c1-c1c(Cl)c(F)cc2c1C[C@](c1ccccc1)([C@@H]1CCCN1)O2
LMB763,CN1N=C(C(=O)N(CC2=CC=CC=C2)CC2=CC=C(C(=O)O)C=C2)C2=C1C1=CC(Cl)=CC=C1OC2,,Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(=O)O)cc2)c2c1-c1cc(Cl)ccc1OC2
Emraclidine,CC1=CC(C)=C2CN(CC2=N1)C(=O)CC1CN(C1)C1=CC=NC(=C1)C(F)(F)F,,Cc1cc(C)c2c(n1)CN(C(=O)CC1CN(c3ccnc(C(F)(F)F)c3)C1)C2
YCT529,CC1=CC=C(/C2=C/C(C)(C)OC3=CC=C(C4=CC=C(C5=CC=C(C(=O)O)C=C5)N4)C=C23)C=C1,,Cc1ccc(C2=CC(C)(C)Oc3ccc(-c4ccc(-c5ccc(C(=O)O)cc5)[nH]4)cc32)cc1
JBJ-09-063,CN1CCC(C2=CC=C(C3=CC=C4C(=C3)C(=O)N(C(C(=O)NC3=NC=CS3)C3=CC(F)=CC=C3O)C4)C=C2)CC1,,CN1CCC(c2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)Nc3nccs3)c3cc(F)ccc3O)C4)cc2)CC1
Sertraline,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,Nervous system disorders(suicide),CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Escitalopram,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Nervous system disorders(suicide),CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Citalopram,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Nervous system disorders(suicide),CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Fluoxetine,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Nervous system disorders(suicide),CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
Paroxetine,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,Nervous system disorders(suicide),Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
Fluvoxamine,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,Nervous system disorders(suicide),COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
Finasteride,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,Nervous system disorders(suicide),CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
doxycycline,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,Nervous system disorders(suicide),C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
lumacaftor,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O,Nervous system disorders(suicide),Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
clozapine,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,Nervous system disorders(suicide),CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,Nervous system disorders(suicide),COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
piroxicam,CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,Nervous system disorders(suicide),CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
formoterol,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,Nervous system disorders(suicide),COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1
venlafaxine,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Nervous system disorders(suicide),COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
Bupropion,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,Nervous system disorders(suicide),CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
quetiapine,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,Nervous system disorders(suicide),OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,Nervous system disorders(suicide),Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
tiagabine,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,Nervous system disorders(suicide),Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C
topiramate,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,Nervous system disorders(suicide),CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1
vigabatrin,NC(CCC(O)=O)C=C,Nervous system disorders(suicide),C=CC(N)CCC(=O)O
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Nervous system disorders(suicide),CC[C@@H](C(N)=O)N1CCCC1=O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,Nervous system disorders(suicide),O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
taselisib,CC(C)N1N=C(C)N=C1C1=CN2CCOC3=CC(=CC=C3C2=N1)C1=CN(N=C1)C(C)(C)C(N)=O,,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1
GS-2278,C[C@@H](OC(NC1=C(C2=NC=C(NC(C3=CN=C(C(F)(F)F)N=C3)=O)C=C2)N=NN1C)=O)C4=C(F)N=CC(F)=C4,Preclinical Neurotoxicity,C[C@@H](OC(=O)Nc1c(-c2ccc(NC(=O)c3cnc(C(F)(F)F)nc3)cn2)nnn1C)c1cc(F)cnc1F
Montelukast,OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Varenicline,C1C2CNCC1C1=C2C=C2N=CC=NC2=C1,,c1cnc2cc3c(cc2n1)C1CNCC3C1
Atomoxetine,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,Nervous system disorders(suicide);Cardiac disorders;Vascular disorders,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Mefloquine,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,,OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1
Brivaracetam,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,Nervous system disorders(suicide),CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1
diazepam,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,Nervous system disorders(suicide),CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
gabapentin,NCC1(CC(O)=O)CCCCC1,Nervous system disorders(suicide),NCC1(CC(=O)O)CCCCC1
pregabalin,CC(C)C[C@H](CN)CC(O)=O,Nervous system disorders(suicide),CC(C)C[C@H](CN)CC(=O)O
Apatinib,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Altiratinib,FC1=CC=C(NC(=O)C2(CC2)C(=O)NC2=C(F)C=C(OC3=CC=NC(NC(=O)C4CC4)=C3)C(F)=C2)C=C1,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
BRD-810,CCC1=C2C(=NN1C)[C@@H](CCN1CCOCC1)OCCCCN1/C(C(=O)O)=C(/CCCO/C3=C/C=C\C4=CC(F)=CC=C34)C3=C1C2=C(Cl)C=C3,safety,CCc1c2c(nn1C)[C@@H](CCN1CCOCC1)OCCCCn1c(C(=O)O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(Cl)c-2c31
ABBV-467,CN1CCN(C[C@@H]2COC3=CC(=C(OCC4=CC=NC(C5=CC=C(OCC6COCCO6)C=C5)=N4)C=C3)C[C@H](C(=O)O)OC3=C4C(=N/C=N/3)/SC(C3=CC=C(F)C=C3)=C/4C3=C(C)C(Cl)=C(C(Cl)=C3C)O2)CC1,cardiac side effects,Cc1c(Cl)c2c(Cl)c(C)c1-c1c(-c3ccc(F)cc3)sc3ncnc(c13)O[C@@H](C(=O)O)Cc1cc(ccc1OCc1ccnc(-c3ccc(OCC4COCCO4)cc3)n1)OC[C@@H](CN1CCN(C)CC1)O2
AMG 176,[H][C@@]12CC[C@@]1([H])[C@@H](OC)/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C1=CC=C3C(=C1)N(C[C@@]1(CCCC4=CC(Cl)=CC=C14)CO3)C2,cardiac side effects,CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3
AMG 397,[H][C@]12CCCCN1CCN(C[C@@]1(OC)/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C3=CC=C4C(=C3)N(C[C@@]3(CCCC5=CC(Cl)=CC=C35)CO4)C[C@]3([H])CC[C@@]13[H])C2,cardiac side effects,CO[C@]1(CN2CCN3CCCC[C@@H]3C2)/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3
AZD5991,CC1=C2C(=NN1C)CSCC1=NN(C)C(=C1)CSC1=C/C3=CC=CC=C3\C(=C/1)OCCC/C1=C(\C(=O)O)N(C)C3=C2C(Cl)=CC=C13,cardiac side effects,Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13
GS-9716,CN1N=C(OC)C(C(N[S@](=O)(C[C@@H](C)C/C=C/[C@H](C)[C@H]2[C@H](C3)CC2)=NC(C4=CC(N3C[C@]5(C6=CC=C(Cl)C=C6CCC5)CO7)=C7C=C4)=O)=O)=C1,cardiac side effects,COc1nn(C)cc1C(=O)N[S@@]1(=O)=NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]2[C@@H](C)/C=C/C[C@H](C)C1)C[C@@]1(CCCc2cc(Cl)ccc21)CO3
sotorasib,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F,"dose toxicity,Diarrhea and liver problems",C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,dose toxicity,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,dose toxicity,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,dose toxicity,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
labetalol,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1,dose toxicity,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
sildenafil,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,dose toxicity,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
erdafitinib,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1,"dose toxicity;For erdafitinib, exposure-response analysis and clinical data indicated that dosages beyond 9 mg once daily are not expected to have increased benefits for efficacy while a dosage of 12 mg once daily resulted in higher rates of exposure-associated adverse events (AEs) and decreased tolerability",COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1
pemigatinib,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F,dose toxicity,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21
Selpercatinib,COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1,"Dose escalation included narrow dose increments of 33% over the range of 20 mg once daily to 240 mg twice a day to allow for precise initial dose-response analysis for safety. The results from the dose-escalation portion showed 0 of 3 patients with dose-limiting toxicities (DLTs) at 160 mg twice a day and 2 of 6 patients with DLTs at 240 mg. Initial safety signals associated with concentration-dependent QTc interval prolongation influenced selection of the twice a day regimen over the initial once-daily regimen. This was based on the potential higher risk of QT interval prolongation with a once-daily regimen compared with a twice a day regimen where maximum plasma concentrations would be lower, but daily exposure could still be matched to once-daily dosing.",COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
zolpidem,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,"FDA is also reminding the public that all drugs taken for insomnia can impair driving and activities that require alertness the morning after use. Drowsiness is already listed as a common side effect in the drug labels of all insomnia drugs, along with warnings that patients may still feel drowsy the day after taking these products. Patients who take insomnia drugs can experience impairment of mental alertness the morning after use, even if they feel fully awake.",Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Tramadol,COC1=CC=CC(=C1)C1(O)CCCCC1CN(C)C,"dose toxicity;Misuse, Overdose, and Suicide;Seizures and the Serotonin Syndrome",COc1cccc(C2(O)CCCCC2CN(C)C)c1
LY2780301,O=C1CC2=C(N3CCC(C4=NC(C5=CC=C(F)C(C(F)(F)F)=C5)=CN4CCN(C)C)CC3)N=CN=C2N1,,CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3c2CC(=O)N3)CC1
BAY1125976,NC(=O)C1=N/N2C(=NC(C3=CC=C(C4(N)CCC4)C=C3)=C2C2=CC=CC=C2)/C=C\1,,NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1
MK-2206,C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N,,NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1
Afuresertib (GSK2110183),CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1,"Rash, nausea, vomiting, diarrhea, hyperglycemia, pneumonia, mouth ulcers",Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl
Capivasertib (AZD5363),NC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1,"Rash, nausea, vomiting, diarrhea, hyperglycemia, pneumonia, mouth ulcers",NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
Ipatasertib (GDC-0068),[H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1,"Rash, nausea, vomiting, diarrhea, hyperglycemia, pneumonia, mouth ulcers",CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1
Miransertib (ARQ-092),NC1=NC=CC=C1C1=NC2=CC=C(N=C2N1C1=CC=C(C=C1)C1(N)CCC1)C1=CC=CC=C1,"Rash, nausea, vomiting, diarrhea, hyperglycemia, pneumonia, mouth ulcers",Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1
Vistusertib (AZD2014),CNC(=O)C1=CC(=CC=C1)C1=CC=C2C(N=C(N=C2N2CCOC[C@@H]2C)N2CCOC[C@@H]2C)=N1,"Fatigue, nausea, vomiting, diarrhea, pneumonia, mouth ulcers, hyperglycemia",CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1
Sapanisertib (MLN0128),CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1,"Fatigue, diarrhea, nausea, vomiting, rash",CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21
loriatinib,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21
brigatinib,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
Ensartinib,C[C@@H](OC1=CC(=NN=C1N)C(=O)NC1=CC=C(C=C1)C(=O)N1C[C@H](C)N[C@H](C)C1)C1=C(Cl)C=CC(F)=C1Cl,,C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(N)nn3)cc2)C[C@H](C)N1
Alectinib,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
crizotinib,[H][C@](C)(OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
mobocertinib,COC1=C(NC2=NC=C(C(=O)OC(C)C)C(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,最常见的不良反应 (>20%) 是腹泻、皮疹、恶心、口腔炎、呕吐、食欲下降、甲沟炎、疲劳、皮肤干燥和肌肉骨骼疼痛。产品标签包括 QTc 延长和尖端扭转型室性心动过速的黑框警告，以及间质性肺病/肺炎、心脏毒性和腹泻的警告。,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
Esketamine,CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl,用于难治性抑郁症患者时，最常见的副作用包括解离、头晕、恶心、嗜睡、焦虑和血压升高,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,neurological,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
Ephedrine,CN[C@@H](C)[C@H](O)c1ccccc1,cardiovascular,CN[C@@H](C)[C@H](O)c1ccccc1
Zimelidine,CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1,"neurological, dermatological",CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1
Ketorolac,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,"renal, hematological",O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Oxyphenisatin acetate,CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3ccccc32)cc1,hepatic,CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3ccccc32)cc1
Sitaxentan,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,hepatic,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2
Pirprofen,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,"hepatic, gastrointestinal",CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Encainide,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1,cardiovascular,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1
Danthron,O=C1c2cccc(O)c2C(=O)c2c(O)cccc21,carcinogenicity,O=C1c2cccc(O)c2C(=O)c2c(O)cccc21
Clioquinol,Oc1c(I)cc(Cl)c2cccnc12,neurological,Oc1c(I)cc(Cl)c2cccnc12
Aristolochic acid,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,renal,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3
Tryptophan,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,hematological,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
Temafloxacin,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,"hepatic, renal, dermatological, hematological",CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
Phenoxypropazine,CC(COc1ccccc1)NN,hepatic,CC(COc1ccccc1)NN
Azaribine,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O,hematological,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
Ethyl nitrite [spirit],CCON=O,hematological,CCON=O
Feprazone,CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,dermatological,CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Cinepazide,COc1cc(/C=C/C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC,hematological,COc1cc(/C=C/C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC
Loperamide,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,gastrointestinal,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
Benzarone,CCc1oc2ccccc2c1C(=O)c1ccc(O)cc1,hepatic,CCc1oc2ccccc2c1C(=O)c1ccc(O)cc1
Diethylstilbestrol,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,reproductive,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
Suloctidil,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,hepatic,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1
Indoprofen,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,"carcinogenicity, gastrointestinal",CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Muzolimine,CC(c1ccc(Cl)c(Cl)c1)N1N=C(N)CC1=O,neurological,CC(c1ccc(Cl)c(Cl)c1)N1N=C(N)CC1=O
Droperidol,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,cardiovascular,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
Aminophenazone cyclamate,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C.O=S(=O)(O)NC1CCCCC1,hematological,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C
Aminoglutethimide,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,multiple,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
Dihydroxymethylfuratrizine,OCN(CO)c1:n:c:c(C=Cc2:o:c(:c:c:2)N(=O)=O):n:n:1,carcinogenicity,O=[N+]([O-])c1ccc(C=Cc2cnc(N(CO)CO)nn2)o1
Vincamine,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,hematological,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32
Rofecoxib,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,cardiovascular,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Indalpine,c1ccc2c(CCC3CCNCC3)c[nH]c2c1,hematological,c1ccc2c(CCC3CCNCC3)c[nH]c2c1
Cerivastatin,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,muscular,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
Fipexide,O=C(COc1ccc(Cl)cc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1,hepatic,O=C(COc1ccc(Cl)cc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1
Dilevalol,C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,hepatic,C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1
Oxyphenisatine,O=C1Nc2ccccc2C1(c1ccc(O)cc1)c1ccc(O)cc1,hepatic,O=C1Nc2ccccc2C1(c1ccc(O)cc1)c1ccc(O)cc1
Thiobutabarbitone,CC[C@H](C)[C@]1(CC)C(=NC(=S)NC1=O)[O-],renal,CC[C@H](C)[C@@]1(CC)C(=O)NC(=S)N=C1O
Triparanol,CCN(CC)CCOc1ccc(C(O)(Cc2ccc(Cl)cc2)c2ccc(C)cc2)cc1,opthalmic,CCN(CC)CCOc1ccc(C(O)(Cc2ccc(Cl)cc2)c2ccc(C)cc2)cc1
Cloforex,CCOC(=O)NC(C)(C)Cc1ccc(Cl)cc1,cardiovascular,CCOC(=O)NC(C)(C)Cc1ccc(Cl)cc1
Thalidomide,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,reproductive,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
Terodiline,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,cardiovascular,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C
Canrenone,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1,carcinogenicity,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1
Sibutramine,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,cardiovascular,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
Terconazole,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,dermatological,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Alatrofloxacin,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21,hepatic,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21
Sulfamethoxypyridazine,COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1,dermatological,COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1
Proxibarbal,C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O,dermatological,C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O
Nefazodone,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,hepatic,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
Moxisylyte,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,hepatic,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Amphetamine,CC(N)Cc1ccccc1,cardiovascular,CC(N)Cc1ccccc1
Chlormadinone,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,carcinogenicity,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Phenylbutazone,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,hematological,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Xenazoic acid,CCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1,hepatic,CCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1
Chlormezanone,CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1,hepatic,CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1
Diamthazole,CCN(CC)CCOc1ccc2nc(N(C)C)sc2c1,neurological,CCN(CC)CCOc1ccc2nc(N(C)C)sc2c1
Difemerine,CN(C)CC(C)(C)OC(=O)C(O)(c1ccccc1)c1ccccc1,multiple,CN(C)CC(C)(C)OC(=O)C(O)(c1ccccc1)c1ccccc1
Sulfacarbamide,NC(=O)NS(=O)(=O)c1ccc(N)cc1,"dermatological, hematological, hepatic",NC(=O)NS(=O)(=O)c1ccc(N)cc1
Trovafloxacin,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,hepatic,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12
Alphacetylmethadol,CC[C@@H](OC(C)=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1,cardiovascular,CC[C@@H](OC(C)=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1
Exifone,O=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O,hepatic,O=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O
Dinoprostone,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,muscular,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O
Hydromorphone,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,multiple,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
Isocarboxazid,Cc1cc(C(=O)NNCc2ccccc2)no1,hepatic,Cc1cc(C(=O)NNCc2ccccc2)no1
Metipranolol,CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C,hematological,CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C
Propoxyphene,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,cardiovascular,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C
Buformin,CCCCNC(=N)NC(=N)N,hematological,CCCCNC(=N)NC(=N)N
Gatifloxacin,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,cardiovascular,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Pifoxime,C/C(=N\O)c1ccc(OCC(=O)N2CCCCC2)cc1,neurological,C/C(=N\O)c1ccc(OCC(=O)N2CCCCC2)cc1
Nomifensine,CN1Cc2c(N)cccc2C(c2ccccc2)C1,hematological,CN1Cc2c(N)cccc2C(c2ccccc2)C1
Rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,cardiovascular,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Methopholine,COc1cc2c(cc1OC)C(CCc1ccc(Cl)cc1)N(C)CC2,opthalmic,COc1cc2c(cc1OC)C(CCc1ccc(Cl)cc1)N(C)CC2
Cianidanol,Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2,hematological,Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2
Pergolide,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,cardiovascular,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Bendazac,O=C(O)COc1nn(Cc2ccccc2)c2ccccc12,hepatic,O=C(O)COc1nn(Cc2ccccc2)c2ccccc12
Lynestrenol,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,carcinogenicity,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
Amoproxan,COc1cc(C(=O)OC(COCCC(C)C)CN2CCOCC2)cc(OC)c1OC,"dermatological, opthalmic",COc1cc(C(=O)OC(COCCC(C)C)CN2CCOCC2)cc(OC)c1OC
Althesin,CC(=O)OCC(=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@@]12C.CC(=O)[C@@H]5CC[C@H]6[C@@H]7CC[C@H]8C[C@@H](O)CC[C@]8(C)[C@H]7C(=O)C[C@@]56C,hematological,CC(=O)OCC(=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@@]12C
Isoxicam,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,dermatological,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1
Bromfenac,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,hepatic,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Chlorphentermine,CC(C)(N)Cc1ccc(Cl)cc1,cardiovascular,CC(C)(N)Cc1ccc(Cl)cc1
Ebrotidine,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1,hepatic,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1
Ximelagatran,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1,hepatic,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1
Zomepirac,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,dermatological,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1
Oxyphenbutazone,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O,hematological,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O
Coumarin,O=c1ccc2ccccc2o1,hepatic,O=c1ccc2ccccc2o1
Methiodal sodium,O=S(=O)([O-])CI.[Na+],muscular,O=S(=O)(O)CI
Pyrrolizidine,C1CC2CCCN2C1,hepatic,C1CC2CCCN2C1
Phenacetin,CCOc1ccc(NC(C)=O)cc1,"carcinogenicity, renal",CCOc1ccc(NC(C)=O)cc1
Bunamiodyl,CCCC(=O)Nc1c(I)cc(I)c(/C=C(\CC)C(=O)O)c1I,renal,CCCC(=O)Nc1c(I)cc(I)c(/C=C(\CC)C(=O)O)c1I
Pentylenetetrazol,C1CCc2nnnn2CC1,neurological,C1CCc2nnnn2CC1
Isaxonine phosphate,CC(C)Nc1ncccn1.O=P(O)(O)O,hepatic,CC(C)Nc1ncccn1
Ibufenac,CC(C)Cc1ccc(CC(=O)O)cc1,hepatic,CC(C)Cc1ccc(CC(=O)O)cc1
Perhexiline,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,"neurological, hepatic",C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
Benziodarone,CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1,hepatic,CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1
Dexfenfluramine,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,cardiovascular,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
Cisapride,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,cardiovascular,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
Proglumide,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1,respiratory,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
Ticrynafen,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,hepatic,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
Clometacin,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,hepatic,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1
Dipyrone,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,hematological,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Phenylpropanolamine,CC(N)C(O)c1ccccc1,cardiovascular,CC(N)C(O)c1ccccc1
Practolol,CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1,dermatological,CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1
Sparfloxacin,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,cardiovascular,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1
Domperidone,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,cardiovascular,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
Polydexide sulfate,[C@@H]1(OCCN(CC)CC)[C@@H](O)[C@H](OCCN(CC)CC)[C@H](O[C@@H]1OC[C@H]2O[C@H](O)[C@H](OCCN(CC)CC)[C@@H](O)[C@@H]2OCC(O)CO[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5OCC[N+](CCN(CC)CC)(CC)CC)CO)CO[C@H]6O[C@@H]([C@@H](OCCN(CC)CC)[C@H](O)[C@H]6O)CO.O=[S]([O-])([O-])=O,opthalmic,CCN(CC)CCO[C@@H]1[C@@H](O)[C@H](OCC(O)CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO[C@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OCC[N+](CC)(CC)CCN(CC)CC)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](CO[C@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@@H](OCCN(CC)CC)[C@H](O)[C@H]3O)[C@@H](OCCN(CC)CC)[C@H](O)[C@H]2OCCN(CC)CC)O[C@@H]1O
Acetanilide,CC(=O)Nc1ccccc1,hematological,CC(=O)Nc1ccccc1
Grepafloxacin,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,cardiovascular,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
Sorivudine,O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)cc1/C=C/Br,hematological,O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)cc1/C=C/Br
Piperazine,C1CNCCN1,carcinogenicity,C1CNCCN1
Terfenadine,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,cardiovascular,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
Remoxipride,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,hematological,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC
Cyclofenil,CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1,hepatic,CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1
Glafenine,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,hematological,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,cardiovascular,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
Troglitazone,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,hepatic,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
Sertindole,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,cardiovascular,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
Chloroform,ClC(Cl)Cl,carcinogenicity,ClC(Cl)Cl
Noscapine,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,carcinogenicity,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
Mebanazine,CC(NN)c1ccccc1,hepatic,CC(NN)c1ccccc1
Levamisole,c1ccc([C@H]2CN3CCSC3=N2)cc1,hematological,c1ccc([C@H]2CN3CCSC3=N2)cc1
Methapyrilene,CN(C)CCN(Cc1cccs1)c1ccccn1,carcinogenicity,CN(C)CCN(Cc1cccs1)c1ccccn1
Etretinate,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,reproductive,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Pronetalol,CC(C)NCC(O)c1ccc2ccccc2c1,carcinogenicity,CC(C)NCC(O)c1ccc2ccccc2c1
Nifedipine,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],cardiovascular,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
Phenformin,N=C(N)NC(=N)NCCc1ccccc1,hematological,N=C(N)NC(=N)NCCc1ccccc1
Dimethylamylamine,CCCCCN(C)C,cardiovascular,CCCCCN(C)C
Fenclofenac,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,dermatological,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl
Prenylamine,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,cardiovascular,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1
Fenclozic acid,O=C(O)Cc1csc(-c2ccc(Cl)cc2)n1,hepatic,O=C(O)Cc1csc(-c2ccc(Cl)cc2)n1
Tegaserod,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,cardiovascular,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12
Oxeladin,CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,carcinogenicity,CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1
Tetrazepam,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,dermatological,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21
Butamben,CCCCOC(=O)c1ccc(N)cc1,dermatological,CCCCOC(=O)c1ccc(N)cc1
Dofetilide,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,cardiovascular,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
Bithionol,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,dermatological,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
Clomacran,CN(C)CCCC1c2ccccc2Nc2ccc(Cl)cc21,hepatic,CN(C)CCCC1c2ccccc2Nc2ccc(Cl)cc21
Sulfathiazole,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,hepatic,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Triazolam,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,neurological,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2
Triacetyldiphenolisatin,CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1,hepatic,CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1
Alclofenac,C=CCOc1ccc(CC(=O)O)cc1Cl,dermatological,C=CCOc1ccc(CC(=O)O)cc1Cl
Alpidem,CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12,hepatic,CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12
Alosetron,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,gastrointestinal,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
Anagestone acetate,CC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C,carcinogenicity,CC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C
Propanidid,CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1,dermatological,CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1
Lumiracoxib,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,hepatic,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Phenolphthalein,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,"carcinogenicity, dermatological",O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21
Thioridazine,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,cardiovascular,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
Thenalidine,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1,hematological,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1
Dihydrostreptomycin,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O,neurological,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O
Clobutinol,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,cardiovascular,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1
Urethane,CCOC(N)=O,carcinogenicity,CCOC(N)=O
Minaprine,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,neurological,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1
Bucetin,CCOc1ccc(NC(=O)CC(C)O)cc1,renal,CCOc1ccc(NC(=O)CC(C)O)cc1
Valdecoxib,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,cardiovascular,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Fenoterol,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,cardiovascular,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1
Tolrestat,COc1ccc2c(C(=S)N(C)CC(=O)O)cccc2c1C(F)(F)F,hepatic,COc1ccc2c(C(=S)N(C)CC(=O)O)cccc2c1C(F)(F)F
Rapacuronium,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1,respiratory,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1
Suprofen,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,renal,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Tolcapone,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,hepatic,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Erythromycin estolate,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,hepatic,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
Benoxaprofen,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,"hepatic, renal",CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
Dithiazanine iodide,CCN1/C(=C/C=C/C=C/c2sc3ccccc3[n+]2CC)Sc2ccccc21.[I-],cardiovascular,CCN1/C(=C/C=C/C=C/c2sc3ccccc3[n+]2CC)Sc2ccccc21
Nitrefazole,Cc1nc([N+](=O)[O-])cn1-c1ccc([N+](=O)[O-])cc1,"hematological, hepatic",Cc1nc([N+](=O)[O-])cn1-c1ccc([N+](=O)[O-])cc1
Nialamide,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,hepatic,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1
Pemoline,NC1=NC(=O)C(c2ccccc2)O1,hepatic,NC1=NC(=O)C(c2ccccc2)O1
Droxicam,CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O,hepatic,CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O
Amineptine,O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21,"hepatic, dermatological",O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21
Pipamazine,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,hepatic,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Neomycin Sulfate,[C@H]4(O[C@@H]2O[C@@H]([C@@H](OC1O[C@H]([C@@H](O)[C@H](O)[C@H]1N)CN)[C@H]2O)CO)[C@H](O[C@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3N)CN)[C@@H](N)C[C@@H](N)[C@@H]4O.O=[S](=O)(O)O,neurological,NC[C@@H]1OC(O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
Benzydamine Hydrochloride,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,opthalmic,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Omeprazole,COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,neurological,COc1ccc2[nH]c([S+](O)Cc3ncc(C)c(OC)c3C)nc2c1
Dicyclomine,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,multiple,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
Dolasetron,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,cardiovascular,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12
Amfepramone Hydrochloride,CCN(CC)C(C)C(=O)c1ccccc1,cardiovascular,CCN(CC)C(C)C(=O)c1ccccc1
Benfluorex,CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,cardiovascular,CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1
Vitamin E,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,hepatic,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
Methandrostenolone,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,multiple,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Sparteine Sulphate,[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@]12[H],reproductive,C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@@H]34)[C@H]2C1
Hydrochlorthiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,cardiovascular,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
Naftidrofuryl Oxalate,CCN(CC)CCOC(=O)[C@@H](Cc1cccc2ccccc12)C[C@@H]1CCCO1,cardiovascular,CCN(CC)CCOC(=O)[C@@H](Cc1cccc2ccccc12)C[C@@H]1CCCO1
Ciprofibrate,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O,muscular,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
Ketoconazole,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,hepatic,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Acitretin,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,reproductive,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Isotretinoin,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,reproductive,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Bromocriptine Mesylate,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O,neurological,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Ethinylestradiol,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,multiple,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
Megestrol Acetate,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,carcinogenicity,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Sulfadimethoxine,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,dermatological,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
Sulfametoxydiazine,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,hematological,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1
Celecoxib,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,cardiovascular,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,cardiovascular,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
Bufexamac,CCCCOc1ccc(CC(=O)NO)cc1,multiple,CCCCOc1ccc(CC(=O)NO)cc1
Indomethacin,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,multiple; gastrointestinal,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,multiple,CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Febarbamate,CCCCOCC(CN1C(=O)NC(=O)C(CC)(c2ccccc2)C1=O)OC(N)=O,hepatic,CCCCOCC(CN1C(=O)NC(=O)C(CC)(c2ccccc2)C1=O)OC(N)=O
Benzbromarone,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,hepatic,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
Cinchophen,O=C(O)c1cc(-c2ccccc2)nc2ccccc12,hepatic,O=C(O)c1cc(-c2ccccc2)nc2ccccc12
Acetylsalicylic Acid,CC(=O)Oc1ccccc1C(=O)O,"hepatic, neurological",CC(=O)Oc1ccccc1C(=O)O
Phenobarbital,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,multiple; dermatological,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
Felbamate,NC(=O)OCC(COC(N)=O)c1ccccc1,neurological,NC(=O)OCC(COC(N)=O)c1ccccc1
Budipine,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,cardiovascular,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
Veralipride,C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC,cardiovascular,C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC
Clorazepate,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,multiple,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O
Camazepam,CN(C)C(=O)OC1N=C(c2ccccc2)c2cc(Cl)ccc2N(C)C1=O,multiple,CN(C)C(=O)OC1N=C(c2ccccc2)c2cc(Cl)ccc2N(C)C1=O
Pentobarbital,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,multiple,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
Amobarbital,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,multiple,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
Aprobarbital,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,respiratory,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O
Secobarbital,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O,multiple,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
Vinbarbital,CC/C=C(\C)C1(CC)C(=O)NC(=O)NC1=O,respiratory,CC/C=C(\C)C1(CC)C(=O)NC(=O)NC1=O
Cyclobarbital,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,multiple,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O
Hexobarbital,CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O,respiratory,CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O
Flunitrazepam,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,multiple,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21
Temazepam,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,respiratory,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21
Pyrithyldione,CCC1(CC)C(=O)C=CNC1=O,multiple,CCC1(CC)C(=O)C=CNC1=O
Dibenzepin Hydrochloride,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21.Cl,carcinogenicity,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21
Tranylcypromine,NC1CC1c1ccccc1,cardiovascular,NC1CC1c1ccccc1
Mianserin,CN1CCN2c3ccccc3Cc3ccccc3C2C1,hematological,CN1CCN2c3ccccc3Cc3ccccc3C2C1
Mepazine Hydrochloride,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,neurological,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
Medifoxamine,CN(C)CC(Oc1ccccc1)Oc1ccccc1,hepatic,CN(C)CC(Oc1ccccc1)Oc1ccccc1
Methamphetamine Hydrochloride,CN[C@@H](C)Cc1ccccc1.Cl,multiple,CN[C@@H](C)Cc1ccccc1
Buprenorphine,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,respiratory,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Tilbroquinol,Cc1cc(Br)c(O)c2ncccc12,hepatic,Cc1cc(Br)c(O)c2ncccc12
Orciprenaline,CC(C)NCC(O)c1cc(O)cc(O)c1,cardiovascular,CC(C)NCC(O)c1cc(O)cc(O)c1
Oxolamine Citrate,CCN(CC)CCc1nc(-c2ccccc2)no1,neurological,CCN(CC)CCc1nc(-c2ccccc2)no1
Zipeprol,COC(CN1CCN(CC(O)C(OC)c2ccccc2)CC1)c1ccccc1,multiple,COC(CN1CCN(CC(O)C(OC)c2ccccc2)CC1)c1ccccc1
Doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,reproductive,CN(C)CCOC(C)(c1ccccc1)c1ccccn1
Nikethamide,CCN(CC)C(=O)c1cccnc1,neurological,CCN(CC)C(=O)c1cccnc1
Gentamicin,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H](N)C[C@@H]2N)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,neurological,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H](N)C[C@@H]2N)O1
Metrizamide,CC(=O)Nc1c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]2O)c(I)c(N(C)C(C)=O)c1I,neurological,CC(=O)Nc1c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]2O)c(I)c(N(C)C(C)=O)c1I
Iophendylate,CCOC(=O)CCCCCCCCC(C)c1ccc(I)cc1,multiple,CCOC(=O)CCCCCCCCC(C)c1ccc(I)cc1
Canthaxanthin,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)CCC2(C)C)C(C)(C)CCC1=O,opthalmic,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)CCC2(C)C)C(C)(C)CCC1=O
Aminorex Fumarate,NC1=NCC(c2ccccc2)O1,"respiratory, cardiovascular",NC1=NCC(c2ccccc2)O1
Adenosine Phosphate,Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O,cardiovascular,Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O
Torcetrapib,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,cardiovascular,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC
Suprifen,CNC(C)C(O)c1ccc(O)cc1,renal,CNC(C)C(O)c1ccc(O)cc1
Beclobrate,CCOC(=O)C(C)(CC)Oc1ccc(Cc2ccc(Cl)cc2)cc1,hepatic,CCOC(=O)C(C)(CC)Oc1ccc(Cc2ccc(Cl)cc2)cc1
Pyrovalerone,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1,hematological; multiple,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
Chlornaphazine,ClCCN(CCCl)c1ccc2ccccc2c1,carcinogenicity,ClCCN(CCCl)c1ccc2ccccc2c1
Timonacic,O=C(O)C1CSCN1,multiple,O=C(O)C1CSCN1
Diiododiethyltin,I[Sn](CC)(CC)I,neurological,CC[Sn](I)(I)CC
Pioglitazone,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,carcinogenicity,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Ribavirin,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,respiratory,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,neurological,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
Cephaloridine,O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12,renal,O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3ccccc3)CS[C@H]12
Etifoxine,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,hepatic,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1
Floctafenine,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2c(C(F)(F)F)cccc12,dermatological,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2c(C(F)(F)F)cccc12
Flubendazole,COC(=O)Nc1nc2cc(C(=O)c3ccc(F)cc3)ccc2[nH]1,reproductive,COC(=O)Nc1nc2cc(C(=O)c3ccc(F)cc3)ccc2[nH]1
Flumequine,CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,carcinogenicity,CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23
Flurothyl,FC(F)(F)COCC(F)(F)F,neurological,FC(F)(F)COCC(F)(F)F
Fominoben,CN(CC(=O)N1CCOCC1)Cc1c(Cl)cccc1NC(=O)c1ccccc1,reproductive,CN(CC(=O)N1CCOCC1)Cc1c(Cl)cccc1NC(=O)c1ccccc1
Hexestrol,CCC(c1ccc(O)cc1)C(CC)c1ccc(O)cc1,carcinogenicity,CCC(c1ccc(O)cc1)C(CC)c1ccc(O)cc1
Indoramin,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,cardiovascular,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1
Iodamide,CC(=O)NCc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I,neurological,CC(=O)NCc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1
Niraparib,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1,,NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12
Lamictal,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,美国食品和药物管理局 (FDA) 对研究结果的审查表明，服用癫痫和精神健康药物拉莫三嗪 (Lamictal) 的心脏病患者发生心律失常（称为心律失常）的风险可能增加。,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
Febuxostat,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,美国食品和药物管理局 (FDA) 提醒公众，一项安全性临床试验的初步结果显示，与另一种名为别嘌醇的痛风药物相比，非布索坦 (Uloric) 可增加心脏相关死亡的风险。,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O
Ziprasidone,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,美国食品和药物管理局 (FDA) 警告说，抗精神病药物齐拉西酮（以商品名 Geodon 及其仿制药销售）与一种罕见但严重的皮肤反应有关，这种反应可能会发展到影响身体的其他部位。DRESS 可能从皮疹开始，然后扩散到身体的各个部位。它可能包括发烧、淋巴结肿大以及肝脏、肾脏、肺、心脏或胰腺等器官的炎症。DRESS 还会导致血液中一种叫做嗜酸性粒细胞的特定类型的白细胞数量高于正常水平。着装会导致死亡。,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,美国食品和药物管理局 (FDA) 警告公众，阿奇霉素（Zithromax 或 Zmax）可引起心脏电活动的异常变化，可能导致潜在致命的不规则心律。虽然几种大环内酯类抗生素具有促心律失常作用并与心源性猝死风险增加相关，但阿奇霉素被认为具有最小的心脏毒性。然而，已发表的心律失常报告表明，阿奇霉素可能会增加心血管死亡的风险。(PMID: 22591294),CC[C@H]1OC(=O)[C@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
Copiktra,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,FDA 警告癌症药物 Copiktra (duvelisib) 可能增加死亡风险和严重副作用,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
umbralisib,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,出于安全考虑，美国食品和药物管理局 (FDA) 已撤回对抗癌药物 Ukoniq (umbralisib) 的批准。Ukoniq 被批准用于治疗两种特定类型的淋巴瘤：边缘区淋巴瘤（MZL）和滤泡性淋巴瘤（FL）。UNITY-CLL 临床试验的更新结果继续显示接受 Ukoniq 的患者死亡风险可能增加。因此，我们确定使用 Ukoniq 治疗的风险大于其益处。,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Donepezil,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2
Semagacestat,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21,,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21
Zanubrutinib,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
Ifenprodil,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1
Xanomeline,CCCCCCOc1nsnc1C1=CCCN(C)C1,,CCCCCCOc1nsnc1C1=CCCN(C)C1
Abarelix,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Ethchlorvynol,CCC(O)(\C=C\Cl)C#C,,C#CC(O)(/C=C/Cl)CC
Methyclothiazide,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,,CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O
Chlorotrianisene,COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1,,COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
Ethoxzolamide,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O,,CCOc1ccc2nc(S(N)(=O)=O)sc2c1
Thiethylperazine,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,,CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2
Dydrogesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C
Dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
Tacrine,NC1=C2CCCCC2=NC2=CC=CC=C12,,Nc1c2c(nc3ccccc13)CCCC2
Acetohexamide,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,,CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
Metocurine iodide,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3
Lindane,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Neurotoxicity,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
Loracarbef,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1
Metharbital,CCC1(CC)C(=O)NC(=O)N(C)C1=O,,CCC1(CC)C(=O)NC(=O)N(C)C1=O
Hexylcaine,CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1,,CC(CNC1CCCCC1)OC(=O)c1ccccc1
Tridihexethyl,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1,,CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1
Bentiromide,OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1,,O=C(O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1
Mephenytoin,CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1,,CCC1(c2ccccc2)NC(=O)N(C)C1=O
Chlormerodrin,COC(CNC(N)=O)C[Hg]Cl,,COC(CNC(N)=O)C[Hg]Cl
Fenfluramine,CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,Cardiotoxicity,CCNC(C)Cc1cccc(C(F)(F)F)c1
Sulfametopyrazine,COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1,,COc1nccnc1NS(=O)(=O)c1ccc(N)cc1
Isoflurophate,CC(C)OP(F)(=O)OC(C)C,,CC(C)OP(=O)(F)OC(C)C
Moricizine,CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1,,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2
Hetacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,,CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,,CC(c1cc2ccccc2s1)N(O)C(N)=O
Benzquinamide,CCN(CC)C(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O,,CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O
Hydroflumethiazide,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F,,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O
Roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
Haloprogin,ClC1=CC(Cl)=C(Cl)C=C1OCC#CI,,Clc1cc(Cl)c(OCC#CI)cc1Cl
Halazepam,FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F
Carprofen,CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1,,CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12
Cinoxacin,CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,,CCn1nc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
Ranitidine,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
Alprenolol,CC(C)NCC(O)COC1=CC=CC=C1CC=C,,C=CCc1ccccc1OCC(O)CNC(C)C
Flupentixol,[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,,OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
Bitolterol,CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C,,Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1
Amlexanox,CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
Ethinamate,NC(=O)OC1(CCCCC1)C#C,,C#CC1(OC(N)=O)CCCCC1
Carphenazine,CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2
Methyprylon,CCC1(CC)C(=O)NCC(C)C1=O,Drug abuse,CCC1(CC)C(=O)NCC(C)C1=O
Trilostane,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O
Cefadroxil,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1
Candicidin,CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1,,CC1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)CC(O)C(C(=O)O)C(O)CC(=O)CC(O)CC(O)CC(O)CC(=O)CCCC(=O)CC(=O)OC1C(C)CC(C)C(O)CC(=O)c1ccc(N)cc1
Amdinocillin,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1,,CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(=O)O
Flecainide,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,,O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
Diphenidol,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
Chlorprothixene,CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12,,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
Bepridil,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Cardiotoxicity,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
Ceftizoxime,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,"Drug interactions,
musculoskeletal",COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
Testosterone propionate,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Drug abuse,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Bezitramide,CCC(=O)N1C(=O)N(C2CCN(CCC(C#N)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C2=CC=CC=C12,Overdose,CCC(=O)n1c(=O)n(C2CCN(CCC(C#N)(c3ccccc3)c3ccccc3)CC2)c2ccccc21
Fencamfamin,CCNC1C2CCC(C2)C1C1=CC=CC=C1,,CCNC1C2CCC(C2)C1c1ccccc1
Ethylestrenol,[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],"Inappropriate use in
malnourished children",CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
Chloral betaine,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,,C[N+](C)(C)CC(=O)O
Etryptamine,CCC(N)CC1=CNC2=CC=CC=C12,,CCC(N)Cc1c[nH]c2ccccc12
Fenproporex,CC(CC1=CC=CC=C1)NCCC#N,"Drug abuse, psychiatric",CC(Cc1ccccc1)NCCC#N
Nimesulide,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,Hepatotoxicity,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
Iproniazid,CC(C)NNC(=O)C1=CC=NC=C1,"Immunologic, liver",CC(C)NNC(=O)c1ccncc1
Lysergic acid diethylamide,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N(CC)CC,,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Methaqualone,CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,Misuse,Cc1ccccc1-n1c(C)nc2ccccc2c1=O
Clofedanol,CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl,,CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl
Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
Nalmefene,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Eflornithine,NCCCC(N)(C(F)F)C(O)=O,,NCCCC(N)(C(=O)O)C(F)F
Triclofos,OP(O)(=O)OCC(Cl)(Cl)Cl,,O=P(O)(O)OCC(Cl)(Cl)Cl
Halcinonide,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Levopropoxyphene,[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1,,CCC(=O)O[C@@](Cc1ccccc1)(c1ccccc1)[C@@H](C)CN(C)C
Mangafodipir,[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1,,Cc1nc(COP(=O)(O)O)cc(CN(CCN(CC(=O)O)Cc2cc(COP(=O)(O)O)nc(C)c2O)CC(=O)O)c1O
Nonoxynol-9,CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1,,CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1
Plicamycin,CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O,,CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1
Azapropazone,[H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C,,C=CC[C@@H]1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Ethyl biscoumacetate,CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O,,CCOC(=O)C(c1c(O)c2ccccc2oc1=O)c1c(O)c2ccccc2oc1=O
Boceprevir,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
Aminopterin,NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N2)C(N)=N1,,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
Formestane,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,,C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Adrafinil,ONC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,O=C(CS(=O)C(c1ccccc1)c1ccccc1)NO
Magaldrate,O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,,O=S(=O)(O)O
Isoxsuprine,C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1,,C[C@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1
Isoaminile,CC(C)[C@@](C[C@H](C)N(C)C)(C#N)C1=CC=CC=C1,,CC(C)[C@](C#N)(C[C@H](C)N(C)C)c1ccccc1
Iotroxic acid,OC(=O)C1=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C(I)C=C1I,,O=C(COCCOCCOCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I
Iopanoic acid,CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O,,CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O
Inositol nicotinate,O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1,,O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H]1OC(=O)c1cccnc1)c1cccnc1
Indenolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC2,,CC(C)NCC(O)COc1cccc2c1C=CC2
Ibuproxam,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO,,CC(C)Cc1ccc(C(C)C(=O)NO)cc1
Hydroxydione,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)CO,,C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)CO)CC[C@@H]12
Hexoprenaline,OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C1=CC(O)=C(O)C=C1,,Oc1ccc(C(O)CNCCCCCCNCC(O)c2ccc(O)c(O)c2)cc1O
Glibornuride,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C,,Cc1ccc(S(=O)(=O)NC(=O)N[C@H]2[C@H]3CC[C@@](C)([C@H]2O)C3(C)C)cc1
Gemeprost,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC,,CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)OC
Fusafungine,[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C,,CC(C)C1OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C1=O
Fluocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Fluclorolone acetonide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CO)O1
Florantyrone,OC(=O)CCC(=O)C1=CC2=C(C=C1)C1=C3C2=CC=CC3=CC=C1,,O=C(O)CCC(=O)c1ccc2c(c1)-c1cccc3cccc-2c13
Fentonium,[H][C@](CO)(C(=O)O[C@]1([H])C[C@]2([H])CC[C@]([H])(C1)[N+]2(C)CC(=O)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=CC=C1,,C[N+]1(CC(=O)c2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2
Fendiline,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1,,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1
Etilefrine,CCNCC(O)C1=CC=CC(O)=C1,,CCNCC(O)c1cccc(O)c1
Ethoheptazine,CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1,,CCOC(=O)C1(c2ccccc2)CCCN(C)CC1
Etamivan,CCN(CC)C(=O)C1=CC(OC)=C(O)C=C1,,CCN(CC)C(=O)c1ccc(O)c(OC)c1
Eprazinone,CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1
Ditazole,OCCN(CCO)C1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,,OCCN(CCO)c1nc(-c2ccccc2)c(-c2ccccc2)o1
Dimetacrine,CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12,,CN(C)CCCN1c2ccccc2C(C)(C)c2ccccc21
Dexetimide,O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1,,O=C1CC[C@@](c2ccccc2)(C2CCN(Cc3ccccc3)CC2)C(=O)N1
Cyclopentamine,CNC(C)CC1CCCC1,,CNC(C)CC1CCCC1
Chlorphenoxamine,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1
Carbazochrome,CN1CC(O)C2=C\C(=N\NC(N)=O)C(=O)C=C12,,CN1CC(O)C2=C/C(=N/NC(N)=O)C(=O)C=C21
Canrenoic acid,[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C,,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O
Butriptyline,CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C,,CC(CC1c2ccccc2CCc2ccccc21)CN(C)C
Brotizolam,CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C1=CC=CC=C1Cl,Tumorigenicity,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2
Benactyzine,CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1
Amylocaine,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1,,CCC(C)(CN(C)C)OC(=O)c1ccccc1
Tixocortol,[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CS
Xanthinol,CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C,,CN(CCO)CC(O)Cn1cnc2c1c(=O)n(C)c(=O)n2C
Difluocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Colfosceril palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
Aurothioglucose,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O
Medrogestone,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Viloxazine,CCOC1=CC=CC=C1OCC1CNCCO1,,CCOc1ccccc1OCC1CNCCO1
Etoperidone,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC,,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC
Zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
Benmoxin,CC(NNC(=O)C1=CC=CC=C1)C1=CC=CC=C1,,CC(NNC(=O)c1ccccc1)c1ccccc1
Iproclozide,CC(C)NNC(=O)COC1=CC=C(Cl)C=C1,,CC(C)NNC(=O)COc1ccc(Cl)cc1
Octamoxin,CCCCCCC(C)NN,,CCCCCCC(C)NN
Pheniprazine,CC(CC1=CC=CC=C1)NN,,CC(Cc1ccccc1)NN
Pivhydrazine,[H]N(CC1=CC=CC=C1)N([H])C(=O)C(C)(C)C,,CC(C)(C)C(=O)NNCc1ccccc1
Safrazine,CC(CCC1=CC2=C(OCO2)C=C1)NN,,CC(CCc1ccc2c(c1)OCO2)NN
Caroxazone,NC(=O)CN1CC2=CC=CC=C2OC1=O,,NC(=O)CN1Cc2ccccc2OC1=O
Strontium ranelate,[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,,N#Cc1c(N(CC(=O)O)CC(=O)O)sc(C(=O)O)c1CC(=O)O
Iopodic acid,CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I,,CN(C)C=Nc1c(I)cc(I)c(CCC(=O)O)c1I
Acetrizoic acid,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C=C1I,,CC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I
Propiolactone,O=C1CCO1,,O=C1CCO1
Cyanocobalamin Co-60,[60Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2,,CC1=C2NC([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O
Cefroxadine,[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,,COC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1
Sarafloxacin,OC(=O)C1=CN(C2=CC=C(F)C=C2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
Asunaprevir,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2,,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
Perflenapent,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
Depreotide,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O,,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
Laropiprant,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,"Higher frequency of
non-fatal but serious side
effects",CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3
Tideglusib,O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1,,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
Inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O
Acetarsol,CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O,Hematologic,CC(=O)Nc1cc([As](=O)(O)O)ccc1O
Carbocromen,CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2,,CCOC(=O)COc1ccc2c(C)c(CCN(CC)CC)c(=O)oc2c1
Edoxudine,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,,CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O
Diphemanil,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1,,C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1
Chlorphenesin carbamate,NC(=O)OCC(O)COC1=CC=C(Cl)C=C1,,NC(=O)OCC(O)COc1ccc(Cl)cc1
Adiphenine,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1
Melphalan flufenamide,CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC1=CC=C(C=C1)N(CCCl)CCCl,,CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1
